RecruitingNCT06391879

Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma

Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma Based on Accurate Genotyping: a Population-based Study


Sponsor

Peking University First Hospital

Enrollment

300 participants

Start Date

Sep 8, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

VHL syndrome is a rare hereditary tumor syndrome caused by mutation of tumor suppressor gene VHL. One of the most important clinical manifestations and main cause of death is VHL-related renal cell carcinoma (RCC). Facing the challenges of multilesion of both kidneys, slow progress and life-long repeated surgeries in VHL-related RCC, individualized prediction of the best surgical treatment time and reduction of times of surgeries are very important to improve the prognosis of patients with VHL syndrome. Therefore, there is an urgent need to establish a more effective and accurate prediction model for the natural course of VHL syndrome. This cohort-study aims to retrospectively and prospectively analyze the factors related to the natural course of VHL-related RCC. At the same time, some patients were selected for prospectively continuous molecular evolution dynamic monitoring after comprehensively considering the results of single cell sequencing, whole genome and metabonomic sequencing. This study will provide scientific basis for accurate diagnosis and treatment of natural course of VHL-related RCC.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This observational study is building a prediction model to understand how kidney tumors in people with VHL disease (a rare inherited condition that causes tumors in multiple organs) grow over time — so doctors can better decide when to watch and wait versus when to operate. **You may be eligible if...** - You have been diagnosed with VHL (Von Hippel-Lindau) syndrome, confirmed either clinically or by genetic testing - You have completed full medical assessments of all organs commonly affected by VHL (eyes, brain, spine, kidneys, etc.) **You may NOT be eligible if...** - You do not meet the clinical criteria for VHL disease or your genetic test was negative - You have another inherited kidney cancer syndrome Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICSingle cell sequencing, whole genome and metabolomic sequencing

The blood specimen of subjects in this cohort would be collected to conduct single cell sequencing, whole genome and metabolomic sequencing.


Locations(1)

Peking University First Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06391879


Related Trials